APOE genotype determines cell-type-specific pathological landscape of Alzheimer's disease

APOE基因型决定阿尔茨海默病细胞类型特异性病理特征

阅读:2
作者:Zonghua Li ,Yuka A Martens ,Yingxue Ren ,Yunjung Jin ,Hiroaki Sekiya ,Sydney V Doss ,Naomi Kouri ,Monica Castanedes-Casey ,Trace A Christensen ,Lindsay B Miller Nevalainen ,Nanaka Takegami ,Kai Chen ,Chia-Chen Liu ,Alexandra Soto-Beasley ,Baayla D C Boon ,Sydney A Labuzan ,Tadafumi C Ikezu ,Yixing Chen ,Alexander D Bartkowiak ,Gisela Xhafkollari ,Allison M Wetmore ,David A Bennett ,Ross R Reichard ,Ronald C Petersen ,Takahisa Kanekiyo ,Owen A Ross ,Melissa E Murray ,Dennis W Dickson ,Guojun Bu ,Na Zhao

Abstract

The apolipoprotein E (APOE) gene is the strongest genetic risk modifier for Alzheimer's disease (AD), with the APOE4 allele increasing risk and APOE2 decreasing it compared with the common APOE3 allele. Using single-nucleus RNA sequencing of the temporal cortex from APOE2 carriers, APOE3 homozygotes, and APOE4 carriers, we found that AD-associated transcriptomic changes were highly APOE genotype dependent. Comparing AD with controls, APOE2 carriers showed upregulated synaptic and myelination-related pathways, preserving synapses and myelination at the protein level. Conversely, these pathways were downregulated in APOE3 homozygotes, resulting in reduced synaptic and myelination proteins. In APOE4 carriers, excitatory neurons displayed reduced synaptic pathways similar to APOE3, but oligodendrocytes showed upregulated myelination pathways like APOE2. However, their synaptic and myelination protein levels remained unchanged or increased. APOE4 carriers also showed increased pro-inflammatory signatures in microglia but reduced responses to amyloid-β pathology. These findings reveal APOE genotype-specific molecular alterations in AD across cell types.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。